Topics

Celgene’s CC-486 Met Primary and Secondary Endpoints in Phase 3 Study as Maintenance Therapy in Newly Diagnosed AML Patients

09:21 EDT 13 Sep 2019 | Speciality Pharma Journal

SUMMIT, N.J.–(BUSINESS WIRE)–Celgene Corporation (NASDAQ: CELG) today announced top-line results from the international phase 3, randomized, double-blind, placebo-controlled study, QUAZAR AML-001. The study evaluated the efficacy and safety of investigational therapy CC-486 as maintenance therapy in patients with newly diagnosed acute myeloid leukemia (AML) who achieved first complete response (CR) or complete response with incomplete …

Original Article: Celgene’s CC-486 Met Primary and Secondary Endpoints in Phase 3 Study as Maintenance Therapy in Newly Diagnosed AML Patients

NEXT ARTICLE

More From BioPortfolio on "Celgene’s CC-486 Met Primary and Secondary Endpoints in Phase 3 Study as Maintenance Therapy in Newly Diagnosed AML Patients"

Quick Search